BenzingaOctober 19, 2026 at 2:56 AM NY8 Days Ago
HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $4
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aardvark Therapeutics (NASDAQ:AARD) with a Neutral and lowers the price target from $6 to $4.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
